Health ❯Healthcare
Patient Care Medical Research Clinical Trials Cancer Oncology Cancer Treatment Cancer Research Clinical Research Public Health Patient Outcomes
Penn researchers report 81% response rates and durable remissions in refractory B-cell lymphoma using huCART19-IL18, a next-generation CAR T therapy with a rapid manufacturing process.